All In Biotech

Free tool

FAERS Monitor: Vykat Xr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216665 or its brand name (Vykat Xr, Diazoxide Choline). Reports on generic versions are filed under their own applications.

Reports

690

Serious

134

19% of reports

Hospitalization

97

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • oedema peripheral135
  • peripheral swelling98
  • weight increased97
  • drug ineffective95
  • blood glucose increased84
  • fluid retention75
  • oedema59
  • hair growth abnormal48
  • hyperglycaemia45
  • hyperphagia45
  • abnormal behaviour44
  • hypertrichosis37
  • aggression36
  • dyspnoea33
  • fatigue27

Reports by year received

View as table
YearReports
2025172
2026518

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,469 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypertrichosisSignal37621.0452.421,844
hyperphagiaSignal45347.9261.815,051
hair growth abnormalSignal48212.9161.99,846
fluid retentionSignal7545.036.33,187
hyperglycaemiaSignal4537.728.41,572
abnormal behaviourSignal4433.925.51,373
oedema peripheralSignal13533.829.04,284
oedemaSignal5933.226.01,813
aggressionSignal3621.916.0700
peripheral swellingSignal9819.416.21,704
blood glucose increasedSignal8413.611.1976
weight increasedSignal9713.211.01,094
drug ineffectiveSignal952.21.865
dyspnoea331.81.311
fatigue271.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.